$ABT

Abbott Laboratories (ABT) and Alphabet (GOOG) announced a multi-year partnership to integrate Abbott’s non-prescription Lingo continuous glucose monitoring data into the Google Health app with Google’s AI Health Coach. The article also cites Abbott Q2 2026 results (sales $12.59B, adj. EPS $1.31, raised FY EPS guidance to $5.45–$5.60) and Alphabet Q2 2026 revenue ($119.8B, up 24%).

Abbott (NYSE: ABT) said it is launching a multi-year partnership with Google Health to integrate Abbott’s over-the-counter Lingo continuous glucose monitor data into the Google Health app. The companies plan an AI-powered Health Coach, plus a large real-world metabolic health study to inform future guidance and Lingo features. Lingo integrations roll out later this year.

Morrone Louis H. (EXECUTIVE VICE PRESIDENT) sold 5,850 shares of ABBOTT LABORATORIES (ABT) at $109.83 ($0.64M total) on 2026-08-11.

Jim Cramer’s “top 10 things to watch” covers July PPI and Fed rate odds, plus company updates: Cisco shares fell after an AI revenue guide; JPMorgan resumed coverage of Salesforce (buy) and Oracle (buy); Cerebras dropped after weaker revenue; Brinker’s guidance lifted its price target; Tapestry fell after guidance; Abbott was upgraded to buy with a higher target.

Wolfe Research downgraded Stryker (SYK) to Peer Perform, citing a difficult second-half outlook after a March cyber disruption and noting the June quarter did not fully catch up. Wolfe said Stryker’s guidance implies 54% of revenue in 2H. Wolfe upgraded Abbott (ABT) to Outperform with a $130 target, citing better 2027 catalysts.

Abbott Laboratories (ABT) said it has a multi-year partnership with Google Health to integrate Abbott’s Lingo glucose biowearable insights into the Google Health app using AI. The collaboration includes personalized metabolic coaching and a planned large-scale metabolic health study. The article also cites Abbott’s forecast of $60.4B revenue and $9.5B earnings by 2029.

Abbott Laboratories opposed a proposed multidistrict litigation (MDL) to centralize lawsuits claiming injuries from its spinal cord stimulators (SCSs). In an Aug. 4 filing to the Judicial Panel on Multidistrict Litigation, Abbott said the cases involve individualized facts and that an MDL would be overbroad and delay resolutions, according to the filing.

Abbott Laboratories shares rose about 1.2% in morning trading after the company announced a multi-year collaboration with Google Health. Abbott’s Lingo continuous glucose monitor data will be integrated into the Google Health app, with personalized coaching via Google Health Coach and a large real-world metabolic study. The move was driven by company-specific news amid a flat U.S. market.

Abbott Laboratories (ABT) reported fiscal Q2 2026 results that beat estimates and raised full-year adjusted diluted EPS guidance to $5.45 to $5.60. Diagnostics sales rose 42% to $3.09 billion, and it reaffirmed comparable sales growth of 6.5% to 7.5%. Medtronic (MDT) reported FY2026 revenue of $36.4 billion and its strongest annual growth in 10 years, while noting tariff headwinds.

A roundup of Q2 earnings trends for major pharma and biotech firms highlights GLP-1 marketing spend, biosimilar and generic competition, and China-related risks. Eli Lilly raised Q2 marketing expenses 25% to $3.43B and lifted year-end revenue guidance to $85B-$87B. Novo Nordisk reported 5M Wegovy pill prescriptions in 30 weeks. Pfizer cut promotional costs and plans $2.5B savings (2027-29).